Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt® ...

INCHEON, Korea I 15, 2025 I Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

The drug, given by injection once monthly or less often, was shown in a mid-stage trial to help overweight or obese patients shed up to 20% of their body weight. Amgen research and development head ...

(Reuters) - Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key ...

Amgen posted a higher quarterly profit on Tuesday, driven by an 11% rise in product sales, and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators ...

The drug, given by injection once monthly or less often ... The company's fourth-quarter sales of Prolia, also known as denosumab, rose 5% to $1.2 billion. Sales of cholesterol-lowering medication ...

Objective Stem cell injection for knee osteoarthritis (KOA) is an emerging new therapy, and we aimed to review its evidence of efficacy. Design Systematic review. Eligibility criteria Criteria for ...

6. Study Links Osteoporosis Injections and Increased MACE in Dialysis Patients In dialysis-dependent patients, those on denosumab (Prolia; Amgen) for fracture risk had a 36% higher MACE rate than ...